Log in

NASDAQ:PHASPhaseBio Pharmaceuticals Stock Price, Forecast & News

$4.65
-0.08 (-1.69 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.49
Now: $4.65
$4.89
50-Day Range
$4.28
MA: $4.89
$6.02
52-Week Range
$2.60
Now: $4.65
$12.34
Volume319,100 shs
Average Volume312,823 shs
Market Capitalization$133.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAS
CUSIPN/A
CIKN/A
Phone610-981-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.36 million
Book Value$2.09 per share

Profitability

Net Income$-39,250,000.00
Net Margins-2,310.60%

Miscellaneous

Employees40
Market Cap$133.83 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

How has PhaseBio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PHAS shares have increased by 48.6% and is now trading at $4.65. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PhaseBio Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PhaseBio Pharmaceuticals.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for PhaseBio Pharmaceuticals.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.10. The company earned $0.32 million during the quarter, compared to the consensus estimate of $0.38 million. PhaseBio Pharmaceuticals had a negative return on equity of 70.50% and a negative net margin of 2,310.60%. View PhaseBio Pharmaceuticals' earnings history.

What price target have analysts set for PHAS?

6 brokers have issued 1-year target prices for PhaseBio Pharmaceuticals' shares. Their forecasts range from $4.00 to $18.00. On average, they expect PhaseBio Pharmaceuticals' share price to reach $13.00 in the next year. This suggests a possible upside of 179.6% from the stock's current price. View analysts' price targets for PhaseBio Pharmaceuticals.

Has PhaseBio Pharmaceuticals been receiving favorable news coverage?

Media coverage about PHAS stock has been trending negative this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PhaseBio Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about PhaseBio Pharmaceuticals.

Are investors shorting PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,250,000 shares, an increase of 13.6% from the June 15th total of 1,980,000 shares. Based on an average trading volume of 696,200 shares, the days-to-cover ratio is presently 3.2 days. Currently, 15.2% of the company's shares are short sold. View PhaseBio Pharmaceuticals' Current Options Chain.

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Amarin (AMRN), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), TapImmune (MRKR), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE) and Dynavax Technologies (DVAX).

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:
  • Mr. Jonathan P. Mow, Pres, CEO & Director (Age 55, Pay $678.78k)
  • Mr. John P. Sharp, Chief Financial Officer (Age 55, Pay $548.51k)
  • Dr. John S. Lee, Chief Medical Officer (Age 52, Pay $581.5k)
  • Mr. Kristopher L. Hanson, VP, Head of Legal & Corp. Sec. (Age 48)
  • Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 55)

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel served as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $4.65.

How big of a company is PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals has a market capitalization of $133.83 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.